ANDA Review Time Cuts Possible Without User Fees, Barr Rep Says
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Generic Drugs could reduce ANDA review times by adding 50 full time equivalents, Barr Laboratories CEO Bruce Downey told the House Energy & Commerce/Health Subcommittee June 13.